Top

Published in:

Open Access 01-12-2022 | NSCLC | Research

The association between ROS1 rearrangement and risk of thromboembolic events in patients with advanced non-small cell lung cancer: a multicenter study in China

Authors: Jiawen Yi, Huang Chen, Jie Li, Xingran Jiang, Yan Xu, Mengzhao Wang, Zheng Wang, Zhenguo Zhai, Yanhong Ren, Yuhui Zhang

Published in: Thrombosis Journal | Issue 1/2022

Abstract

Background

According to several studies, ROS1 rearrangement is associated with thrombotic risk in non-small cell lung cancer (NSCLC). However, there is no clear understanding of the predictors and prognostic impact of thromboembolic events (TEEs) in patients with advanced ROS1 rearrangement NSCLC.

Methods

A total of 47 newly diagnosed advanced NSCLC patients with ROS1 rearrangement from four Chinese hospitals were retrospectively included and were evaluated for TEEs incidence, characteristics, predictors, as well as response to therapies and overall survival (OS).

Results

Of the 47 enrolled patients, 23.4% (n = 11) patients developed TEEs. Among them, 7 of 11 patients (64%) developed pulmonary embolism (PE), and 5 patients (45%) experienced recurrent TEEs. In multivariate analysis, D-dimer was associated with the occurrence of TEEs in ROS1 rearranged NSCLC (HR 1.16, 95% CI 1.08–1.23, P < 0.001). Median progression-free survival (PFS) after first-line ROS1 tyrosine kinase inhibitors (TKIs) therapy was significantly longer in patients without TEEs than in those developing TEEs (26 months vs. 12 months, P = 0.0383). Furthermore, patients with TEEs had a shorter OS period than those without TEEs (29.8 months vs. not estimable, P = 0.0647).

Conclusion

The results of this multicenter study indicated that advanced NSCLC patients with ROS1 rearrangement were more likely to experience PE and TEEs recurrence. And patients with TEEs tended to have a worse prognosis. Furthermore, an elevated D-dimer level suggested a hypercoagulable state in NSCLC patients with ROS1 rearrangement.

Tagalakis V, Levi D, Agulnik JS, Cohen V, Kasymjanova G, Small D. High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients. J Thorac Oncol. 2007;2(8):729–34. https://doi.org/10.1097/JTO.0b013e31811ea275.CrossRefPubMed

Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22. https://doi.org/10.1001/jama.293.6.715.CrossRefPubMed

Zugazagoitia J, Biosca M, Oliveira J, Olmedo ME, Dómine M, Nadal E, et al. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer. Eur Respir J. 2018;51(5). https://doi.org/10.1183/13993003.02431-2017.

Connolly GC, Dalal M, Lin J, Khorana AA. Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer. 2012;78(3):253–8. https://doi.org/10.1016/j.lungcan.2012.09.007.CrossRefPubMed

Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–64. https://doi.org/10.1001/archinte.166.4.458.CrossRefPubMed

Dou F, Li H, Zhu M, Liang L, Zhang Y, Yi J, et al. Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer. Respir Res. 2018;19:88. https://doi.org/10.1186/s12931-018-0791-2.CrossRefPubMedPubMedCentral

Al-Samkari H, Leiva O, Dagogo-Jack I, Shaw A, Lennerz J, Iafrate AJ, et al. Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC. J Thorac Oncol. 2020;15(9):1497–506. https://doi.org/10.1016/j.jtho.2020.04.033.CrossRefPubMed

Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). Lancet. 2016;387(10026):1415–26. https://doi.org/10.1016/S0140-6736(16)00004-0.CrossRefPubMed

Ng TL, Smith DE, Mushtaq R, Patil T, Dimou A, Yang S, et al. ROS1 gene rearrangements are associated with an elevated risk of Peridiagnosis thromboembolic events. J Thorac Oncol. 2019;14(4):596–605. https://doi.org/10.1016/j.jtho.2018.12.001.CrossRefPubMed

10.

Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, et al. ROS1-rearranged non-small-cell lung Cancer is associated with a high rate of venous thromboembolism: analysis from a phase II, prospective, multicenter, two-arms trial (METROS). Clin Lung Cancer. 2020;21(1):15–20. https://doi.org/10.1016/j.cllc.2019.06.012.CrossRefPubMed

11.

Alexander M, Pavlakis N, John T, O'Connell R, Kao S, Hughes B, et al. A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. Lung Cancer. 2020;142:34–40. https://doi.org/10.1016/j.lungcan.2020.01.017.CrossRefPubMed

12.

Muñoz-Unceta N, Zugazagoitia J, Manzano A, Jiménez-Aguilar E, Olmedo ME, Cacho JD, et al. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1. Eur J Cancer. 2020;141:193–8. https://doi.org/10.1016/j.ejca.2020.10.002.CrossRefPubMed

13.

Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015;4:156–64. https://doi.org/10.3978/j.issn.2218-6751.2014.11.11.CrossRefPubMedPubMedCentral

14.

Liu C, Yu H, Chang J, Chen H, Li Y, Zhao W, et al. Crizotinib in Chinese patients with ROS1-rearranged advanced non–Small-cell lung Cancer in routine clinical practice. Target Oncol. 2019;14:315–23. https://doi.org/10.1007/s11523-019-00636-6.CrossRefPubMedPubMedCentral

15.

Sun JM, Kim TS, Lee J, Park YH, Ahn JS, Kim H, et al. Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy. Lung Cancer. 2010;69(3):330–6. https://doi.org/10.1016/j.lungcan.2009.11.015.CrossRefPubMed

16.

Malgor RD, Bilfinger TV, Labropoulos N. A systematic review of pulmonary embolism in patients with lung cancer. Ann Thorac Surg. 2012;94(1):311–6. https://doi.org/10.1016/j.athoracsur.2012.03.025.CrossRefPubMed

17.

van Es N, Ay C, Jara-Palomares L. Screening for occult Cancer in patients with venous thromboembolism: past, present, and future. Hamostaseologie. 2020;40(3):270–9. https://doi.org/10.1055/a-1150-2286.CrossRefPubMed

18.

Piran S, Schulman S. Management of recurrent venous thromboembolism in patients with cancer: a review. Thromb Res. 2018;164(Suppl 1):S172–172S177. https://doi.org/10.1016/j.thromres.2017.12.019.CrossRefPubMed

19.

Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27(29):4839–47. https://doi.org/10.1200/JCO.2009.22.3271.CrossRefPubMedPubMedCentral

20.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–82. https://doi.org/10.1182/blood-2010-02-270116.CrossRefPubMed

21.

Alexander M, Ball D, Solomon B, MacManus M, Manser R, Riedel B, et al. Dynamic thromboembolic risk modelling to target appropriate preventative strategies for patients with non-Small cell lung Cancer. Cancers (Basel). 2019;11(1). https://doi.org/10.3390/cancers11010050.

22.

Pabinger I, van Es N, Heinze G, Posch F, Riedl J, Reitter EM, et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 2018;5(7):e289–289e298. https://doi.org/10.1016/S2352-3026(18)30063-2.CrossRefPubMedPubMedCentral

23.

Liu Y, Wang W, Wu F, Gao G, Xu J, Li X, et al. High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations. Transl Lung Cancer Res. 2021;10(3):1512–24. https://doi.org/10.21037/tlcr-20-1290.CrossRefPubMedPubMedCentral

Title: The association between ROS1 rearrangement and risk of thromboembolic events in patients with advanced non-small cell lung cancer: a multicenter study in China
Authors: Jiawen Yi
Huang Chen
Jie Li
Xingran Jiang
Yan Xu
Mengzhao Wang
Zheng Wang
Zhenguo Zhai
Yanhong Ren
Yuhui Zhang
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: NSCLC
Tyrosine Kinase Inhibitors
NSCLC
Phlebothrombosis
Tyrosine Kinase Inhibitors
Published in: Thrombosis Journal / Issue 1/2022
Electronic ISSN: 1477-9560
DOI: https://doi.org/10.1186/s12959-022-00417-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study

Prevalence and risk factor of post-operative lower extremities deep vein thrombosis in patients undergoing gynecologic surgery: a single-institute cross-sectional study

Clinical significance of neutrophil extracellular traps biomarkers in thrombosis

Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial

Low risk of haematomas with intramuscular vaccines in anticoagulated patients: a systematic review with meta-analysis

Effect of heparin treatment on pulmonary embolism and in-hospital death in unvaccinated COVID-19 patients without overt deep vein thrombosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials